| Bethge, Wolfgang A |
| Recruiting | 3 | 210 | Europe | MC0518, BAT | medac GmbH | Steroid-refractory Acute Graft-versus-host Disease | 08/27 | 08/30 | | |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
| Recruiting | 1/2 | 48 | Europe | MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells | Miltenyi Biomedicine GmbH | Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 29 | Europe | MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells | Miltenyi Biomedicine GmbH, Miltenyi Biomedicine GmbH | SLE - Systemic Lupus Erythematosus | 08/25 | 08/27 | | |
